anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The COVID-19 pandemic prompted immense work on the investigation of the SARS-CoV-2 virus. Rapid, accurate, and consistent interpretation of generated data is thereby of fundamental concern. Ontologies-structured, controlled, vocabularies-are designed to support consistency of interpretation, and thereby to prevent the development of data silos. This paper describes how ontologies are serving this purpose in the COVID-19 research domain, by following principles of the Open Biological and Biomedical Ontology (OBO) Foundry and by reusing existing ontologies such as the Infectious Disease Ontology (IDO) Core, which provides terminological content common to investigations of all infectious diseases. We report here on the development of an IDO extension, the Virus Infectious Disease Ontology (VIDO), a reference ontology covering viral infectious diseases. We motivate term and definition choices, showcase reuse of terms from existing OBO ontologies, illustrate how ontological decisions were motivated by relevant life science research, and connect VIDO to the Coronavirus Infectious Disease Ontology (CIDO). We next use terms from these ontologies to annotate selections from life science research on SARS-CoV-2, highlighting how ontologies employing a common upper-level vocabulary may be seamlessly interwoven. Finally, we outline future work, including bacteria and fungus infectious disease reference ontologies currently under development, then cite uses of VIDO and CIDO in host-pathogen data analytics, electronic health record annotation, and ontology conflict-resolution projects.
The present invention discloses a Chinese medicine for curing acute icterohepatitis and a preparation method thereof. The Chinese medicine of the present invention comprises the following components measured by weight percentages: 10% to 80% of desmodii styracifolii, 5% to 60% of giant knotweed rhizome, 5% to 30% of common selfheal fruit-spike, 0 to 20% of tuckahoe and 0 to 10% of Chinese date. In the Chinese medicine of the present invention, the desmodii styracifolii is used as a main material of which the medicinal characteristic of removing dampness by diuresis and inducing diuresis is utilized to make dampness and heat exhausted by urination. Additionally, the giant knotweed rhizome is used as a supplementary material, of which the function of purging the pathogenic fire and relaxing the bowels makes dampness and heat exhausted by excrement. The common selfheal fruit-spike can remove pathogenic heat from blood and is good at removing heat from the liver. The main material and the supplementary material are added with the tuckahoe for strengthening the spleen, strengthen the middle warmer, disinhibit water, inducing diuresis and excreting dampness. The Chinese date strengthens the spleen and the stomach, so the Chinese date moderates the medicinal properties of the medicines and prevents the spleen and the stomach from injuring by bitter cold when the Chinese date is used. The medicines which are compatible clear heat, eliminate damp, lead damp and heat to be exhausted by urination and excrement, make damp and heat spontaneously eliminated, and together perform the functions of clearing away heat and toxic materials, removing dampness by diuresis and eliminating jaundice. Accordingly, the Chinese medicine of the present invention has obvious effect of curing acute icterohepatitis, wide medicine source and low cost, and is a good special Chinese medicine for curing acute icterohepatitis.
The present invention relates to laminaria which is the general name of seaweed plants of the sea tangle type. The present invention discloses a laminaran granule which is prepared from laminarin, a substance with high activity in laminaria, is easy to absorb by human bodies and is suitable for food and medicines for diabetes patients and obesity patients, and a preparation process of the laminaran granule. The preparation process of the laminaran granule comprises the following steps: cleaning, airing and cutting up fresh laminaria, and placing the laminaria in a leaching tank; adding water to boiling the laminaria, leaching the laminaria, and filtering the leaching liquor; carrying out adsorptive separation with macroporous resin; carrying out eluting operation with edible alcohol; carrying out adsorptive separation to the eluent with a polyamide pillar; carrying out eluting and concentrating operation with alcohol, and carrying out spraying and drying operation to prepare the laminarin powdered extract. The laminarin extractum whose laminarin content is more than or equal to 80% is compounded with xylitol and other sugar-free type fillings. Additionally, a proper amount of adhesive agent or natural sweetening agent accounting for 0.2 to 0.5% of the total weight is added. Through uniform mixing operation, boiling and granulating operation, drying operation and sterilizing operation, the novel biologic product, namely a laminarin granule is prepared.
As knowledge of the gut microbiome has expanded our understanding of the symbiotic and dysbiotic relationships between the human host and its microbial constituents, the influence of gastrointestinal (GI) microbes both locally and beyond the intestine has become evident. Shifts in bacterial populations have now been associated with several conditions including Crohn's disease (CD), Ulcerative Colitis (UC), irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's Disease, liver diseases, obesity, metabolic syndrome, anxiety, depression, and cancers. As the bacteria in our gut thrive on the food we eat, diet plays a critical role in the functional aspects of our gut microbiome, influencing not only health but also the development of disease. While the bacterial microbiome in the context of disease is well studied, the associated gut phageome-bacteriophages living amongst and within our bacterial microbiome-is less well understood. With growing evidence that fluctuations in the phageome also correlate with dysbiosis, how diet influences this population needs to be better understood. This review surveys the current understanding of the effects of diet on the gut phageome.
Corticosteroid administration has been associated with a variety of toxicities, including osteonecrosis and Cushing's Syndrome, in patients with HIV infection. The prevalence of these toxicities has led to speculation that protease inhibitors impair the cytochrome P450 (CYP) 3A4-mediated metabolism of corticosteroids leading to an increase in their systemic exposure and toxicity. Conversely, reduced corticosteroid exposure may be expected when these drugs are coadministrated with CYP3A4 inducers such as the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. Despite the hypothesized interaction between antiretroviral medications and corticosteroids, drug interactions between agents from these classes have not been formally investigated. The objectives of this study are (1) to determine the impact of the HIV protease inhibitor ritonavir on the pharmacokinetics of prednisolone after administration of oral prednisone to healthy volunteers and (2) to determine the respective influences of chronic dosing with lopinavir-ritonavir (LPV/r) and efavirenz (EFV) on prednisolone pharmacokinetics in HIV+ individuals taking a single dose of prednisone. For the HIV-negative healthy volunteer portion of the study, 10 HIV-negative study subjects will receive a single 20 mg dose of prednisone before, and after 3 and 14 days of ritonavir exposure at 200 mg twice daily. Blood and urine will be collected over 24 hrs after prednisone administration to determine prednisolone pharmacokinetics and renal elimination. Blood will also be collected for determination of MDR1 genotype, which may influence prednisolone disposition. For the portion of the study conducted in HIV-infected volunteers, 3 groups of 10 subjects will be recruited to receive a single 20 mg dose of prednisone followed by serial blood sampling for prednisolone concentrations. The 3 groups will consist of (1) individuals receiving and HIV treatment regimen (for at least 30 days) that includes LPV/r (2) individuals receiving an HIV treatment regimen (for at least 30 days) that includes EFV and (3) individual receiving no antiretroviral treatment or treatment devoid of HIV protease inhibitors or NNRTIs. Prednisolone concentrations will be determined by validated high performance chromatographic methods. Non-compartmental methods will be used to characterize prednisolone pharmacokinetics in all study groups. Pharmacokinetic parameter values will be compared using ANOVA with post-hoc testing. Geometric mean data with 90% confidence intervals will be reported. This study will characterize, for the first time, the influence of antiretroviral medications on the pharmacokinetics of a corticosteroid medication (prednisolone).
The study period will be determined by the completion of the predetermined sample size, with two interim analyses planned when 35% (n=274) and 70% (n=548) of the target sample size is achieved to calculate conditional power. If conditional power is estimated to be lower than 15% at first interim analysis or lower than 30% in the second interim analysis, the trial will be stopped due to futility. The study will be performed in Abu Dhabi-Fertility clinic. During the period of this prospective study, euploid blastocysts of enough quality that have been biopsied only on Day-5 for PGT-A, will be warmed for single blastocyst transfer. The patient´s endometrial preparation protocol for FET will be restricted to HRT only. The study will be double-blinded (blinded to patient and doctor performing transfer).
A) An oil which naturally contains gamma-linolenic acid, optionally enriched with gamma-linolenic acid itself or with an ester of this acid and B) Medium chain triglycerides i.e. 6-12C fatty acid esters of glycerol. The compsn. is characterised in that it contains at least one vitamin B12 group constituent, pref. a liposoluble form, esp. dibencozyl palmitate or methylcobalamin parmitate. The compsns. may also contain vitamin A, riboflavin tetrabutyrate, ascorbyl palmitate and antioxidants, such as vitamin E. Compsn. for use in dietics, resuscitation and therapeutics, which provides a readily metabolised energy supply in cases of denutrition, lepid digestion and metabolism troubles, such as diabetes. The compsn. may be administered as a food supplement or may be used orally, enterally or parenterally in association with suitable neutral vehicles.
The invention discloses a cooling itch-relieving alga mint skin nourishing powder, and relates to the technical field of skincare products. The powder is composed of the following components in parts by weight: 35 to 45 parts of mint extract, 8 to 12 parts of propolis powder, 8 to 12 parts of nano diatomite, 15 to 25 parts of seaweed meal, 10 to 20 parts of modified water caltrop powder, 8 to 12 parts of talcum powder, 1 to 3 parts of sophora flavescens total alkali, 1 to 3 parts of borneol, 0.5 to 1 part of kudzu vine root extract, 1 to 3 parts of clove bark powder, 0.5 to 1 part of pine pollen, 1 to 3 parts of purple potato powder, and 1 to 3 parts of curcumin. The components mentioned above are evenly mixed and filled in bottles. The powder can be painted on the skin and has the functions of cooling, relieving itch, and preventing mosquito biting. The powder is made of natural plants and is manufactured by a modern processing technology, and the formula is scientific and reasonable. The powder can provide overall protection on skin, the irritant effect of the powder on the skin is small, the cooling and itch-relieving effect is good, and thus the skin comfort level is high.
The present invention relates to a composition for the prevention, amelioration or treatment of non-alcoholic fatty liver disease (NAFLD), comprising a Roseburia spp. strain, a Bifidobacterium spp. strain, or extracellular vesicles (EVs) derived therefrom. The Roseburia spp. strain, the Bifidobacterium spp. strain, or the EVs derived therefrom, according to the present invention, can restore liver function, ameliorate liver steatosis and inflammation, and suppress liver fibrosis, and thus can be provided as a composition for the prevention, amelioration or treatment of NAFLD.
Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
In many European and other high-income, Western countries, condom use has been decreasing among youth. A variety of promotional strategies to increase condom use exists. Our systematic review aimed to identify effective elements in interventions aimed at increasing condom use in youth. We searched databases (2010-2021) for intervention studies promoting condom use among youth in Western, high-income countries. The primary outcome was condom use; the secondary outcome was sexually transmitted infection (STI) diagnoses. Effectiveness per intervention was defined based on the percentage of comparisons that showed significant increases in condom use and significant decreases in STIs. We compared the effectiveness of interventions for different participant-, intervention- and methodological characteristics. We included 74 papers describing 85 interventions in the review. Overall, the median intervention effectiveness was 33.3% (interquartile range = 0%-66.7%) for condom use and 0% (interquartile range = 0%-100%) for STI diagnoses. Intervention effectiveness for condom use was significantly higher in interventions tailored towards females and males specifically, compared with interventions applied to both sexes combined. Our findings show the difficulty in designing effective interventions to increase condom use among youth. Interventions aimed at either females or males were more effective in increasing condom use.
Early detection of exacerbations by COPD patients initiating prompt interventions has shown to be clinically relevant. Until now, research failed to identify the effectiveness of a written individualized Action Plan (AP) to achieve this. The current multicenter, single-blind RCT with a follow-up period of 6 months, evaluates the hypothesis that individualized AP's reduce exacerbation recovery time. Patients are included from regular respiratory nurse visits and allocated to either usual care or an additional AP providing individualized treatment prescriptions (pharmaceutical and non-pharmaceutical) related to a colour coded symptom status (reinforcement at 1 and 4 months). Although usually not possible in self-management trials, we ensured blinding of patients, using a modified informed consent procedure in which patients give consent to postponed information. Exacerbations in both study arms are defined using the Anthonisen symptom diary-card algorithm. The Clinical COPD Questionnaire (CCQ) is assessed every 3-days. CCQ-recovery time of an exacerbation is our primary outcome. Additionally, healthcare utilisation, anxiety, depression, treatment delay, and self-efficacy are assessed at baseline, 6 and 12 months.
A four-year-old Labrador Retriever was presented for intermittent tachycardia. The electrocardiogram showed sinus rhythm conducted with ventricular pre-excitation and short runs of orthodromic atrioventricular reciprocating tachycardia. Four months later, the rhythm degenerated into a symptomatic sustained tachycardia, suspected to be pre-excited atrial fibrillation, a potentially life-threatening rhythm in the presence of an accessory pathway with a short refractory period. Two days after initiating oral diltiazem, the dog deteriorated and represented with sustained orthodromic atrioventricular reciprocating tachycardia, which was terminated by a precordial chest thump. It proceeded to sinus rhythm with ventricular pre-excitation followed by an episode of pre-excited focal atrial tachycardia. A bolus of lidocaine IV successfully restored sinus rhythm and sotalol treatment was started. The dog clinically recovered but died spontaneously 24 h later. This is the first case report that describes spontaneous pre-excited focal atrial tachycardia.
NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Acid esters of citric or tartaric acid with aliphatic polyhydric alcohols containing at least three hydroxyl groups are added to dentifrices as tartar dissolving agents.  The esters, for instance the sorbite ester of citric acid may be prepared in accordance with Specifications 449,185 and 466,814, [both in Group IV].  Other agents, such as watersoluble metaphosphates or pyrophosphates, serving to dissolve insoluble calcium compounds may also be added. The dentifrices may contain the usual mechanical cleansing agents, binding agents, capillary active substances, disinfectants and flavours, examples of which are given: all these additions should be substantially free from calcium.  The dentifrice should preferably be neutral or weakly acid.  According to an example, a dentifrice contains sorbitol ester of citric acid, aluminium silicate, talc, bolus, kaolin, silica gel and glycerin.  The prior use of phenolsulphonic acid sodium salt as a tartar-removing agent is referred to.
While the number of infectious zoonotic disease outbreaks has been rising, their impact on civil war and social conflict is poorly understood. This study addresses this fundamental limitation using a geolocated monthly dataset on 22 zoonotic diseases in Africa. Zoonotic disease is a key driver of new epidemics, making such pathogens a useful test case. Results suggest that over the January 1997 to December 2019 period, zoonotic disease was negatively associated with state initiation of civil conflict and positively associated with social conflict involving identity militias. Additional analyses find that the effect for identity militias is consistent with a causal interpretation. Rebel violence is not significantly associated with outbreaks. The results are robust to endogeneity concerns and additional sensitivity analyses.
Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
The invention discloses a heat-resistant candida albicans peptide and a preparation method and application thereof. The sequence of the anti-candida tropicalis peptide is shown in a sequence table SEQ ID No. 1. The preparation method comprises the following steps: and analyzing antifungal sequences in an APD database, and counting the charge, the length, the amino acid composition and the hydrophobicity ratio. Then, amino acid combinations are counted, and the occurrence frequency of the combination of GGL, GLL, LKK and KKL is high, meanwhile, the occurrence frequency of glycine at the 1 st position, leucine at the 2 nd position, and lysine at the 7 th position and the 11 th position is very high, so that the antibacterial peptide is designed based on the principle. In the minimum inhibitory concentration test, the antibacterial agent has good antibacterial activity on candida tropicalis, and the MIC value is 2 mu M. The results show that the design mode has wide application prospect in the future.
To examine whether an EMA/EMI condition, relative to an EMA-only and a minimal assessment-only condition, decreases incidents of sexual assault, risky sexual behavior, and alcohol use among freshman women (N=288). It is hypothesized that the 6-week EMA/EMI condition, relative to the other conditions, will be associated with lower rates of assault, risky sexual sex, and substance use from baseline to a 6-month followup.
Refractory AML is associated with poor prognosis. Allogeneic stem cell transplantation is considered as the only curative therapy. Unfortunately, conventional transplantation protocol usually has high relapse rate and high nor-relapse mortality. In previous studies, the investigators established a protocol using intensive chemotherapy (cladribine, cytarabine and etoposide) to reduced the leukemia burden followed by reduced intensity conditioning regimen of Flu-Bu3 with 7 day interval. All patients received maintenance therapy. The 1-year relapse rate was less than 20% but toxicity such as lethal infection was documented in sizable part of patients. In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with following modifications: 1) dose of cytarabine and etoposide are reduced to 1g/m2 and 100mg/m2 daily; 2) conditioning regimen is based on Flu-Bu2 combined with addition of melphalan (100mg/m2) or total marrow irradiation (TMI) in case of contra-indication for busulfan or melphalan; 3) Venetoclax is added to the chemotherapy and conditioning regimen. The modifications intend to reduce both the toxicities and relapse, which may turn into a benefit of disease-free survival (DFS). This is designed as a phase II multi-center prospective study to evaluate the feasibility and efficacy of the protocol.
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
Participants will be asked to eat ad libitum between the hours of 9:30 - 18:30 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 9:30 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.